2013-01-21 18:56:00 -

BAGSVAERD, DENMARK -- (Marketwire) -- 01/21/13 --



Company announcement No 6 / 2013:
hugin.info/2013/R/1671082/543181.pdf : hugin.info/2013/R/1671082/543181.pdf





This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:



(i) the releases contained herein are protected by copyright and
other applicable laws; and



(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.



Source: Novo Nordisk A/S via Thomson Reuters ONE



[HUG#1671082]




Further information
Media:
Mike Rulis
+45 4442 3573
Email Contact : www2.marketwire.com/mw/emailprcntct?id=66C68AD46F9E0ECB

Ambre Morley (US)
+1 609 216 5240
Email Contact : www2.marketwire.com/mw/emailprcntct?id=D999A72202C94823

Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact : www2.marketwire.com/mw/emailprcntct?id=F8877E82B17D454E

Frank Daniel Mersebach
+45 4442 0604
Email Contact : www2.marketwire.com/mw/emailprcntct?id=42B07D1822C37E82

Lars Borup Jacobsen
+45 3075 3479
Email Contact : www2.marketwire.com/mw/emailprcntct?id=5E5461CB476DBC6B

Jannick Lindegaard (US)
+1 609 786 4575
Email Contact : www2.marketwire.com/mw/emailprcntct?id=6A45478E63F326DD